Jin Rong Jie Zi Xun·2025-12-31 02:41Group 1 - The core viewpoint of the news is the online launch of the innovative oral antiviral drug, Mapasavir Capsules (brand name: Yilikang®), by Health元药业集团 on JD Health platform, aimed at providing a new treatment option for influenza [1][3]. - Influenza, caused by the influenza virus, poses a significant health threat, especially to vulnerable populations such as children, the elderly, and those with chronic diseases, necessitating timely antiviral treatment to mitigate risks [3]. - Mapasavir Capsules utilize a novel mechanism as a cap-dependent endonuclease inhibitor, effectively blocking the replication of the influenza virus at an early stage, offering broad-spectrum antiviral activity against both type A and B influenza viruses [3]. Group 2 - Health元药业集团 is an innovative pharmaceutical group focused on unmet clinical needs, with over 20 first-class innovative drugs in its portfolio, more than 10 of which are in critical phases of development [4]. - The online launch of Yilikang® marks the beginning of a deeper collaboration between Health元 and JD Health, leveraging JD Health's marketing resources and supply chain to enhance patient access to the drug [4]. - Future collaborations will focus on comprehensive influenza prevention and treatment, including improving drug accessibility, patient education, and influenza warning systems, aiming to create an integrated health service ecosystem [4].